NanoViricides (NNVC) vs TransCode Therapeutics (RNAZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NanoViricides (NNVC) has outperformed TransCode Therapeutics (RNAZ) over the past year, losing 8.4% versus a loss of 88.4%. Over five years, NNVC leads with a -73.2% price change compared with -100.0% for RNAZ. NanoViricides is the larger company by market cap ($33.4 million vs $29.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NNVC | RNAZ |
|---|---|---|
| Share price | $1.31 | $1.71 |
| Market cap | $33.44M | $28.95M |
| 1-day change | -9.03% | -2.84% |
| YTD return | +15.93% | -74.96% |
| 1-year return | -8.39% | -88.45% |
| 5-year return | -73.16% | -100.00% |
| EPS (TTM) | $-0.41 | $-52.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.23 | $15.94 |
| 52-week low | $0.85 | $1.52 |
| Distance from 52-week high | -41.26% | -89.27% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +358.02% | — |
| Average volume | 445.00K | 50.19K |
| Shares outstanding | 25.52M | 16.93M |
| Employees | 7 | 12 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NNVC has outperformed RNAZ by 80.1 percentage points over the past year.
About NanoViricides
NNVC stock →NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.
Healthcare · Biotechnology · 7 employees
About TransCode Therapeutics
RNAZ stock →TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.
Healthcare · Biotechnology · 12 employees
NNVC vs RNAZ FAQ
Which is bigger, NanoViricides or TransCode Therapeutics?
NanoViricides (NNVC) is larger, with a market capitalization of $33.44M compared with $28.95M for TransCode Therapeutics (RNAZ).
Which stock has performed better over the past year, NNVC or RNAZ?
NNVC returned -8.39% over the past 12 months, compared with -88.45% for RNAZ (price return, excluding dividends). Past performance does not predict future results.
Are NanoViricides and TransCode Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.